See more : MKB Nedsense NV (NEDSE.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Cyclo Therapeutics, Inc. (CYTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cyclo Therapeutics, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Oasis Petroleum Inc. (OAS) Income Statement Analysis – Financial Results
- Beyond Air, Inc. (XAIR) Income Statement Analysis – Financial Results
- Caesarstone Ltd. (CSTE) Income Statement Analysis – Financial Results
- Shanghai 2345 Network Holding Group Co., Ltd. (002195.SZ) Income Statement Analysis – Financial Results
- Sio Gene Therapies Inc. (SIOX) Income Statement Analysis – Financial Results
Cyclo Therapeutics, Inc. (CYTH)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cyclotherapeutics.com
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08M | 1.38M | 1.59M | 903.38K | 1.01M | 1.01M | 1.24M | 1.50M | 950.46K | 1.57M | 1.69M | 1.04M | 1.03M | 802.37K | 623.87K | 494.94K | 751.18K | 542.31K | 454.36K | 464.69K | 394.53K | 522.37K | 289.43K | 384.59K |
| Cost of Revenue | 98.46K | 138.93K | 156.08K | 66.40K | 75.49K | 105.03K | 132.92K | 198.43K | 124.43K | 272.64K | 426.02K | 139.68K | 273.76K | 114.66K | 110.83K | 99.32K | 118.40K | 125.19K | 66.66K | 78.83K | 45.43K | 84.48K | 34.03K | 99.22K |
| Gross Profit | 977.95K | 1.24M | 1.43M | 836.98K | 931.71K | 906.45K | 1.10M | 1.30M | 826.03K | 1.29M | 1.27M | 905.27K | 758.09K | 687.71K | 513.04K | 395.62K | 632.77K | 417.13K | 387.70K | 385.87K | 349.10K | 437.89K | 255.40K | 285.37K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% | 89.62% | 89.26% | 86.80% | 86.91% | 82.61% | 74.84% | 86.63% | 73.47% | 85.71% | 82.24% | 79.93% | 84.24% | 76.92% | 85.33% | 83.04% | 88.48% | 83.83% | 88.24% | 74.20% |
| Research & Development | 14.18M | 9.00M | 9.15M | 6.10M | 4.87M | 2.71M | 2.29M | 1.86M | 658.51K | 94.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.66M | 7.81M | 6.50M | 3.68M | 3.43M | 2.43M | 2.62M | 2.64M | 2.22M | 1.53M | 639.54K | 560.17K | 799.60K | 678.64K | 693.33K | 520.06K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 3.90K | 13.06K | 18.34K | 5.01K | 5.89K | 5.64K | 7.85K | 7.16K | 7.57K | 10.90K | 8.91K | 10.81K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.83M | 7.82M | 6.52M | 3.68M | 3.44M | 2.44M | 2.63M | 2.65M | 2.23M | 1.55M | 648.45K | 570.98K | 799.60K | 678.64K | 693.33K | 520.06K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 548.79K |
| Other Expenses | 0.00 | 30.50K | 27.54K | 19.95K | 13.98K | 13.95K | 19.77K | 130.95K | 202.02K | 217.52K | 188.76K | 159.93K | 32.75K | 20.94K | 20.65K | 22.87K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Operating Expenses | 21.04M | 16.85M | 15.70M | 9.80M | 8.32M | 5.16M | 4.95M | 4.65M | 3.09M | 1.86M | 837.21K | 730.91K | 832.35K | 699.58K | 713.98K | 542.93K | 439.10K | 350.68K | 500.32K | 664.78K | 263.50K | 240.54K | 279.11K | 575.21K |
| Cost & Expenses | 21.13M | 16.99M | 15.85M | 9.86M | 8.40M | 5.27M | 5.08M | 4.85M | 3.22M | 2.13M | 1.26M | 870.59K | 1.11M | 814.24K | 824.81K | 642.25K | 557.51K | 475.86K | 566.97K | 743.61K | 308.93K | 325.02K | 313.14K | 674.43K |
| Interest Income | 0.00 | 12.47K | 3.41K | 19.80K | 12.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.51K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.60K | 31.29K | 33.67K | 53.87K | 61.80K | 25.81K | 4.31K | 0.00 | 1.82K | 10.75K | 11.05K | 13.96K | 12.03K | 22.60K | 30.92K | 35.44K | 28.29K | |
| Depreciation & Amortization | 19.28K | 19.48K | 16.83K | 12.76K | 5.68K | 10.12K | 9.27K | 107.10K | 169.03K | 152.45K | 148.04K | 142.64K | 32.75K | 20.94K | 20.58K | 22.87K | 24.37K | 27.46K | 35.01K | 27.76K | 37.82K | 24.19K | 51.29K | 26.41K |
| EBITDA | -20.03M | -15.60M | -14.27M | -8.95M | -7.39M | -4.24M | -3.82M | -4.09M | -2.23M | -406.57K | 486.82K | 303.65K | -39.21K | 12.72K | -172.55K | -188.55K | 218.04K | -63.32K | -77.60K | -251.15K | 90.92K | 221.54K | 27.58K | -66.02K |
| EBITDA Ratio | -1,860.90% | -1,145.03% | -897.54% | -992.49% | -719.16% | -419.60% | -309.54% | -215.26% | -220.57% | -26.15% | 34.14% | 30.34% | -4.02% | 1.13% | -28.91% | -25.14% | 26.28% | 46.31% | -56.50% | 4.17% | 29.51% | 42.57% | 8.63% | -69.09% |
| Operating Income | -20.05M | -15.61M | -14.27M | -8.96M | -7.39M | -4.27M | -3.84M | -4.21M | -2.41M | -562.31K | 336.65K | 157.49K | -74.26K | -11.87K | -200.94K | -239.47K | 193.67K | -45.90K | -112.61K | -278.91K | 85.60K | 197.35K | -23.71K | -289.84K |
| Operating Income Ratio | -1,862.69% | -1,134.76% | -899.77% | -991.85% | -733.80% | -421.84% | -310.51% | -279.85% | -253.22% | -35.87% | 19.88% | 15.07% | -7.20% | -1.48% | -32.21% | -48.38% | 25.78% | -8.46% | -24.78% | -60.02% | 21.70% | 37.78% | -8.19% | -75.36% |
| Total Other Income/Expenses | -7.25K | 171.00K | 3.41K | 19.80K | 12.03K | 11.77K | 10.26K | -17.95K | -24.62K | -30.37K | -51.74K | -58.29K | -23.51K | -662.00 | 7.81K | 26.24K | 9.89K | -168.28K | 165.15K | -282.58K | -15.63K | -31.77K | -32.83K | 171.41K |
| Income Before Tax | -20.06M | -15.45M | -14.29M | -8.94M | -7.53M | -4.26M | -3.83M | -4.22M | -2.43M | -592.69K | 284.91K | 99.20K | -97.77K | -12.53K | -193.13K | -213.23K | 203.55K | -101.83K | 52.54K | -561.49K | 69.98K | 165.58K | -56.54K | -315.83K |
| Income Before Tax Ratio | -1,863.36% | -1,123.08% | -900.94% | -989.80% | -747.87% | -420.68% | -309.68% | -281.04% | -255.81% | -37.81% | 16.83% | 9.49% | -9.47% | -1.56% | -30.96% | -43.08% | 27.10% | -18.78% | 11.56% | -120.83% | 17.74% | 31.70% | -19.54% | -82.12% |
| Income Tax Expense | 0.00 | -171.00K | 18.52K | -18.53K | 141.75K | 11.77K | 0.00 | 28.60K | 120.00K | 33.67K | 80.00K | 25.00K | 25.81K | 25.00K | 0.00 | 200.00K | -450.00K | 168.28K | 225.00K | 282.58K | -225.00K | 31.77K | 90.17K | 195.00K |
| Net Income | -20.06M | -15.28M | -14.31M | -8.92M | -7.67M | -4.26M | -3.83M | -4.22M | -2.55M | -592.69K | 204.91K | 74.20K | -97.77K | -37.53K | -193.13K | -413.23K | 653.55K | -101.83K | -172.46K | -561.49K | 294.98K | 165.58K | -113.88K | -510.83K |
| Net Income Ratio | -1,863.36% | -1,110.65% | -902.10% | -987.75% | -761.94% | -420.68% | -309.68% | -281.04% | -268.44% | -37.81% | 12.10% | 7.10% | -9.47% | -4.68% | -30.96% | -83.49% | 87.00% | -18.78% | -37.96% | -120.83% | 74.77% | 31.70% | -39.35% | -132.82% |
| EPS | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| EPS Diluted | -1.23 | -1.81 | -2.25 | -5.58 | -7.09 | -5.20 | -5.32 | -6.67 | -4.54 | -1.17 | 1.00 | 1.00 | -0.27 | -0.11 | -0.67 | -1.76 | 3.60 | -0.69 | -1.44 | -7.76 | 5.00 | 3.00 | -2.59 | -13.80 |
| Weighted Avg Shares Out | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
| Weighted Avg Shares Out (Dil) | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M | 817.57K | 720.37K | 633.54K | 562.09K | 505.43K | 371.66K | 366.80K | 358.07K | 337.11K | 287.51K | 235.33K | 179.20K | 148.15K | 120.18K | 72.32K | 50.05K | 47.91K | 43.89K | 37.02K |
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Niemann-Pick disease - Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs...
Cyclo Therapeutics, Inc. (CYTH) Reports Q3 Loss, Lags Revenue Estimates
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.29 per share a year ago.
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or...
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are...
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services...
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the...
Cyclo Therapeutics, Inc. (CYTH) Reports Q2 Loss, Misses Revenue Estimates
Cyclo Therapeutics, Inc. (CYTH) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.33 per share a year ago.
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a...
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that two abstracts have been...
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been...
Source: https://incomestatements.info
Category: Stock Reports